Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis
New England Journal of Medicine · 12.06.2025 · 392 (22) · 2193-2202
DOI: 10.1056/nejmoa2414108 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 12.06.2025. Verfasst von Luca Richeldi und 16 weiteren Autor:innen. Beteiligte Einrichtung: Unità Operativa Complessa di Pneumologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome. Hauptthemen laut MEDLINE: Idiopathic Pulmonary Fibrosis, Phosphodiesterase 4 Inhibitors. Die Arbeit wurde bisher 302-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Unità Operativa Complessa di Pneumologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome.
- Clinical Research Center, Mihara General Hospital, Saitama, Japan.
- Nippon Medical School, Tokyo.
- National Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, Claude Bernard University Lyon 1, Unité Mixte de Recherche 754, European Reference Network for Rare Respiratory Dise…
- Center for Pulmonary Medicine, Department of Pneumology, Mainz University Medical Center, Mainz, Germany.
- Pulmonary, Critical Care, and Sleep Medicine, Marienhaus Clinic Mainz, Mainz, Germany.
ORCID-Profile: Vincent Cottin, Marlies S Wijsenbeek
Zitieren
APA
Richeldi, L., Azuma, A., Cottin, V., Kreuter, M., Maher, T. M., Martinez, F. J., Oldham, J. M., Valenzuela, C., Clerisme-Beaty, E., Gordat, M., Wachtlin, D., Liu, Y., Schlecker, C., Stowasser, S., Zoz, D. F., Wijsenbeek, M. S., & FIBRONEER-IPF Trial Investigators (2025). Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis. New England Journal of Medicine, 392(22), 2193-2202. https://doi.org/10.1056/nejmoa2414108
Vancouver
Richeldi L, Azuma A, Cottin V, Kreuter M, Maher TM, Martinez FJ, et al. Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis. New England Journal of Medicine. 2025;392(22):2193-2202. doi:10.1056/nejmoa2414108
BibTeX
@article{Richeldi2025,
author = {Richeldi, Luca and Azuma, Arata and Cottin, Vincent and Kreuter, Michael and Maher, Toby M and Martinez, Fernando J and Oldham, Justin M and Valenzuela, Claudia and Clerisme-Beaty, Emmanuelle and Gordat, Maud and Wachtlin, Daniel and Liu, Yi and Schlecker, Christina and Stowasser, Susanne and Zoz, Donald F and Wijsenbeek, Marlies S and FIBRONEER-IPF Trial Investigators, FIBRONEER-IPF Trial Investigators},
title = {Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis},
journal = {New England Journal of Medicine},
year = {2025},
volume = {392},
number = {22},
pages = {2193--2202},
doi = {10.1056/nejmoa2414108}
}
EUVIMED